1. Product Overview: Mavixen® is a fixed-dose combination antiviral medicine containing Glecaprevir and Pibrentasvir, used for the treatment of chronic Hepatitis C virus (HCV) infection across multiple genotypes.

2. Composition: Glecaprevir 100 mg / Pibrentasvir 40 mg | Dosage Form: Tablet

3. Pharmacological Class: Direct-Acting Antiviral (DAA) – NS3/4A Protease Inhibitor + NS5A Inhibitor

4. Mechanism of Action: Glecaprevir inhibits the HCV NS3/4A protease enzyme, while Pibrentasvir inhibits the NS5A protein, together blocking viral replication and assembly, leading to elimination of HCV from infected cells.

5. Indications: Chronic Hepatitis C virus (HCV) infection (all major genotypes) | Treatment of compensated liver disease associated with HCV

6. Dosage & Administration: As directed by physician or hepatology specialist only | Oral use | Usually taken once daily with food | Complete full prescribed course

7. Clinical Benefits: High cure rate for Hepatitis C | Suppresses viral replication | Improves liver function | Reduces risk of cirrhosis and liver complications

8. Contraindications: Hypersensitivity to Glecaprevir, Pibrentasvir, or any component of the formulation | Severe hepatic impairment (Child-Pugh C)

9. Precautions: Liver function monitoring required | Not recommended in severe liver disease | Use cautiously in patients with co-infections (HBV reactivation risk)

10. Drug Interactions: May interact with rifampin, certain anticonvulsants, and herbal products like St. John’s Wort

11. Special Populations: Use in pregnancy and lactation only if clearly needed and prescribed | Pediatric use as per specialist guidance

12. Adverse Effects: Headache | Fatigue | Nausea | Diarrhea | Mild elevation of liver enzymes

13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children

14. Packaging: Tablet blister pack

15. Manufacturer: Everest Pharmaceutical Ltd.